DARWIN EU® - Characterisation of pharmacogenetic testing data in routine healthcare

First published: 14/10/2026

Last updated: 24/11/2026

Study Ongoing

Administrative details

EU PAS number

EUPAS1000001139

Study ID

1000001139

DARWIN EU® study

Yes

Study countries

- Croatia
- Estonia
- Spain
- United Kingdom

United States

Study status

Ongoing

Contact details

Study institution contact

Natasha Yefimenko study@darwin-eu.org

Study contact

study@darwin-eu.org

Primary lead investigator

Cindy Porras

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 13/08/2026

Actual: 13/08/2026

Study start date

Planned: 06/10/2026

Actual: 06/10/2026

Date of final study report

Planned: 26/03/2027

Study protocol

DARWIN EU_Protocol_P5-C1-022.pdf (1.31 MB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Main study objective:

1. To describe the frequency of pharmacogenetic testing within the DARWIN EU® Data Partner Network, by data source and calendar year.
2. To describe the availability and summarised results of pharmacogenetic tests, by type of pharmacogenetic test and data source.
3. To characterise individuals with a record of pharmacogenetic test in terms of demographic characteristics, comorbidities, and drugs prescribed before and

after testing, overall and by pharmacogenetic test.

Data management

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No